Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI trained on 127,000 ECGs to predict deadly heart rhythms

NCT ID NCT07644715

Knowledge-focused Sponsor: Groupe Hospitalier Pitie-Salpetriere Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is not testing a drug or treatment. Instead, researchers are using artificial intelligence to analyze electrocardiogram (ECG) data from over 127,000 people. The goal is to create computer models that can quickly and accurately predict life-threatening heart rhythm problems, such as long QT syndrome and heart inflammation caused by certain cancer drugs. The AI tools are being developed for research purposes only and will not be used to guide patient care during the study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to AI tools that help doctors quickly spot dangerous heart rhythms from ECGs, potentially saving lives.
What could go wrong
This is an early research study using existing data, not a treatment trial. The AI models may not work well in real-world settings or on all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 127,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects from existing and ongoing ECG cohorts contributing to ECGInsight, including healthy volunteers and patients with cardiovascular diseases, cancer/ICI exposure, LQT/TdP and ICI-myocarditis-relevant phenotypes.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * subjects included in participating existing or ongoing ECG cohorts made available to ECGInsight * availability of ECG data (digital waveform or scanned/paper ECG suitable for digitization) and relevant clinical/demographic metadata * data use permitted by applicable ethical, regulatory, contractual and GDPR requirements. Exclusion Criteria: * datasets or individual records for which required approvals, data-sharing agreements, de-identification/anonymization, or minimum ECG/metadata quality requirements are not met. No interventional study treatment is assigned.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiac rhythm disease long QT syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmia Immune checkpoint inhibitor-related myocarditis Long QT syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CIC-2503

    RECRUITING

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.